PNPLA3 and fatty liver disease: Moreover, a recent study indicates that the effects of the PNPLA3 I148M variant on hepatic steatosis may arise not only from its gain of function as an ATGL inhibitor but also from its loss of function in facilitating TG secretion under lipogenic conditions, suggesting a potentially broader interplay.40